LTC Properties Inc vs Organon & Co. Common Stock — how do they compare? LTC Properties Inc trades at $43.09 (market cap $2.31B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and LTC Properties Inc pays the higher dividend (5.31%). Which is the better fit depends on your goals — on Pluang, investors hold LTC Properties Inc for 89 Days and Organon & Co. Common Stock for 0 Days on average.
| LTC | OGN | |
|---|---|---|
Market Cap | $2.31B | $3.62B |
Volume | 323,404 | 2,892,999 |
Sector | Real Estate | Health |
52-Week High | $43.50 | $13.81 |
52-Week Low | $34.04 | $5.70 |
Typical Hold Time | 89 Days | 0 Days |
Enterprise Value | $3.05B | $11.04B |
Dividend Yield | 5.31% | 0.58% |
Signals from Pluang's Aura AI — not financial advice
LTC Properties trades at $43.20, up 0.35% with a bullish technical signal and strong fundamental metrics including 38.93% net income margin and 12.11% ROE. Recent acquisitions totaling $360 million accelerate the SHOP portfolio transition, while consistent monthly dividends of $0.19 provide income stability. Revenue growth continues with 2025 revenue reaching $263 million, though profit margins have moderated from historical highs.
The outlook remains positive with analyst consensus target of $49.67 representing 15% upside potential. Key risks include rising interest rates impacting REIT valuations and execution challenges in portfolio transformation. The stock offers balanced risk-reward with income generation and growth potential from strategic acquisitions in the seniors housing sector.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →